Overview

A Phase 1/2a Study of PER-001 in Participants With Open-Angle Glaucoma

Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Perfuse Therapeutics, Inc.